ReviewCellular & molecular biology letters2026
The role of ECM mechanics in cancer mechanotransduction through unraveling the molecular machinery of integrins, FAK, and YAP signaling.
Review in Cellular & molecular biology letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mechanotransduction, the process by which cells convert mechanical stimuli into biochemical signals, is fundamental for maintaining tissue homeostasis and regulating physiological functions. The extracellular matrix (ECM) serves as a critical mediator of mechanotransduction, with its mechanical properties influencing cellular behaviour and function through complex molecular machinery. This comprehensive review examines the role of ECM mechanics in disease mechanotransduction, focusing on the molecular machinery of integrins, focal adhesion kinase (FAK) and YAP signaling pathways. We explore the structure and composition of the ECM, including detailed analysis of key components such as collagens, elastin, glycoproteins, proteoglycans, hyaluronic acid and matrix metalloproteinases. The review elucidates how integrins function as key mediators of mechanotransduction, the role of FAK in signal transduction, and the mechanosensitive functions of YAP/TAZ signaling. We examine the intricate crosstalk between these mechanotransduction pathways and their dysregulation in cancer. Finally, we discuss emerging therapeutic strategies targeting mechanotransduction pathways and the challenges and opportunities for translating mechanotransduction research into clinical interventions. Understanding these complex mechanotransduction networks is crucial for developing novel therapeutic approaches to treat diseases characterized by altered tissue mechanics and dysregulated cellular responses to mechanical cues.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.